用单时间点68Ga-FAPI-46 PET/CT预测90Y-FAPI-46肿瘤吸收剂量
结果显示两者高度相关,但68Ga预测值倾向于低于90Y参考值,作者认为可用于诊断分层与患者筛选,个体化给药前仍需治疗中验证。
要点
- 68Ga-FAPI-46预测的肿瘤摄取、TIAC与吸收剂量与90Y参考值高度相关。
- 68Ga预测值整体偏低,肿瘤吸收剂量比值平均为0.77±0.35。
- 预测值可辅助诊断分层与患者选择,个体化给药前需治疗中验证。
核心结论
- 90Y-FAPI-46 PET/CT与68Ga-FAPI-46 PET/CT的肿瘤摄取、TIAC和肿瘤吸收剂量高度相关,但68Ga-FAPI-46 PET/CT的数值倾向于低于90Y-FAPI-46 PET/CT。
- 68Ga-FAPI-46 PET/CT的预测值可帮助临床医生进行诊断分层和患者选择,但在任何给药活度个体化之前仍需治疗中验证。
研究设计与样本
- 在PET图像上识别肿瘤,并在低剂量CT上测量解剖肿瘤体积。
- 以90Y-FAPI-46数据计算注射时外推肿瘤摄取、时间积分活度系数(TIAC)和肿瘤吸收剂量作为参考值,并用单时间点剂量学模型由68Ga-FAPI-46数据计算相应预测值进行比较。
主要发现
- 用单时间点68Ga-FAPI-46 PET/CT计算预测值时,全部病灶的90Y-FAPI-46平均有效半衰期为8.44±1.73 h。
- 预测值与参考值之比(68Ga-FAPI-46数据除以90Y-FAPI-46数据)在肿瘤摄取、TIAC和肿瘤吸收剂量分别为0.93±0.39、0.77±0.35和0.77±0.35。
- Bland-Altman分析中,肿瘤摄取、TIAC和肿瘤吸收剂量百分比差异的平均差异(偏倚)±SD分别为-16.11%±43.28%(95%CI,-100.90至68.73%;Spearman ρ=0.91;P<0.0001)、-32.60%±41.26%(95%CI,-113.50至48.26%;Spearman ρ=0.91;P<0.0001)和-33.35%±40.19%(95%CI,-112.10至45.43%;Spearman ρ=0.77;P<0.0001)。
关键数值与推荐
- 全部病灶的90Y-FAPI-46平均有效半衰期为8.44±1.73 h。
- 肿瘤摄取预测值/参考值比为0.93±0.39,TIAC为0.77±0.35,肿瘤吸收剂量为0.77±0.35。
- Bland-Altman偏倚:肿瘤摄取-16.11%±43.28%,TIAC-32.60%±41.26%,肿瘤吸收剂量-33.35%±40.19%。
- 相关性:肿瘤摄取与TIAC的Spearman ρ均为0.91(P<0.0001),肿瘤吸收剂量ρ=0.77(P<0.0001)。
临床怎么用
- 可利用单时间点68Ga-FAPI-46 PET/CT预测90Y-FAPI-46的肿瘤摄取、TIAC与肿瘤吸收剂量,辅助诊断分层和患者选择。
- 因68Ga-FAPI-46预测值倾向于低于90Y-FAPI-46参考值,在个体化给药活度前仍需治疗中剂量学验证。
局限性
- 预测值基于单时间点剂量学模型,且68Ga-FAPI-46预测值系统性偏低,个体化给药前仍需治疗中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiolabeled fibroblast activation protein (FAP)-targeting peptides, such as 90Y-FAPI-46, have increasingly been used to treat various tumor entities, with preliminary reports indicating therapeutic responses with acceptable toxicity profiles. Dosimetry can be used to maximize antitumor capability and minimize side effects. The aim of this study was to investigate whether 90Y-FAPI-46 tumor dosimetry can be predicted by diagnostic 68Ga-FAPI-46 PET/CT data. Methods: Fourteen patients with 24 lesions underwent a single-time-point 68Ga-FAPI-46 PET/CT scan and 3 90Y-FAPI-46 PET/CT scans for dosimetry within a 3-mo interval. Tumors were identified on PET images, and the anatomic tumor volume was measured on low-dose CT. Tumor uptake extrapolated at time of injection, time-integrated activity coefficient (TIAC), and tumor absorbed dose were calculated as reference values using 90Y-FAPI-46 data and compared with the corresponding predicted values using 68Ga-FAPI-46 data by means of a single-time-point dosimetry model. Correlations between 90Y-FAPI-46- and 68Ga-FAPI-46-based values were assessed. Results: In calculating the predicted values using a single-time-point 68Ga-FAPI-46 PET/CT, the mean effective half-life of 90Y-FAPI-46 across all lesions was 8.44 ± 1.73 h. The mean ± SD ratio (i.e., the predicted values using 68Ga-FAPI-46 data divided by the reference 90Y-FAPI-46 data) were 0.93 ± 0.39, 0.77 ± 0.35, and 0.77 ± 0.35 for tumor uptake, TIAC, and tumor absorbed dose, respectively. In the Bland-Altman analysis, mean differences (bias) ± SD of the percent differences of tumor uptake, TIAC, and tumor absorbed dose were -16.11% ± 43.28% (95% CI, -100.90 to 68.73%; Spearman ρ = 0.91; P < 0.0001), -32.60% ± 41.26% (95% CI, -113.50 to 48.26%; Spearman ρ = 0.91; P < 0.0001), and -33.35% ± 40.19% (95% CI, -112.10 to 45.43%; Spearman ρ = 0.77; P < 0.0001), respectively. Conclusion: Tumor uptake, TIAC, and tumor absorbed dose on 90Y-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/CT were highly correlated, although the values on 68Ga-FAPI-46 PET/CT tended to be lower than those on 90Y-FAPI-46 PET/CT. Predicted values on 68Ga-FAPI-46 PET/CT can help clinicians with diagnostic stratification and patient selection, with intratherapeutic verification remaining necessary before any individualization of administered activity.
引用
- Watanabe, Jentzen, Herrmann, et al. Predicting [90Y]Y-FAPI-46 Tumor Absorbed Dose from Single-Time-Point [68Ga]Ga-FAPI-46 PET/CT Imaging. J Nucl Med. 2026. PMID: 42957204. doi:10.2967/jnumed.126.273258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。